[ad_1]
Pfizer’s COVID-19 vaccine has received priority review for full approval by the Food Drug Administration for Americans 16 and older, Pfizer and BioNTech announced Friday.
Why is this important: Full approval of the Pfizer vaccine could help bolster the U.S. vaccination effort, as many people are reluctant to receive the vaccine as part of its emergency use status, the Boston Globe notes.
Stay on top of the latest market trends and economic information with Axios Markets. Subscribe for free
Inventory: As of Friday, the United States had recorded more than 33.9 million cases of COVID and 608,432 deaths, according to John Hopkins University.
Go further: Pfizer to seek FDA clearance for third dose of coronavirus vaccine
More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free
[ad_2]
Source link